Literature DB >> 25670372

Blood-brain barrier: an impediment to neuropharmaceuticals.

J T Henderson1, M Piquette-Miller.   

Abstract

The blood-brain barrier (BBB) serves as a highly selective barrier separating the central nervous system from the systemic circulation. Although contributing to neurological health, the BBB restricts the ability of drugs to reach their site of action and thus presents a major challenge to the treatment of neurological disorders. Advances in our understanding of the complexity of the BBB have fostered development of novel pharmacometric models and drug delivery strategies to better predict and improve therapeutic access.
© 2015 ASCPT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25670372     DOI: 10.1002/cpt.77

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.

Authors:  Jing Li; Jianmei Wu; Xun Bao; Norissa Honea; Youming Xie; Seongho Kim; Alex Sparreboom; Nader Sanai
Journal:  Clin Cancer Res       Date:  2017-09-19       Impact factor: 12.531

Review 2.  Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications.

Authors:  Fanuel T Hagos; Solomon M Adams; Samuel M Poloyac; Patrick M Kochanek; Christopher M Horvat; Robert S B Clark; Philip E Empey
Journal:  Exp Neurol       Date:  2019-02-21       Impact factor: 5.330

3.  Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases.

Authors:  Jing Li; Jun Jiang; Xun Bao; Vineet Kumar; Stephen C Alley; Scott Peterson; Anthony J Lee
Journal:  Clin Cancer Res       Date:  2022-08-02       Impact factor: 13.801

4.  Psoriatic arthritis and depressive symptoms: does systemic inflammation play a role?

Authors:  Enrico De Lorenzis; Gerlando Natalello; Dario Bruno; Giacomo Tanti; Maria Rosaria Magurano; Donatella Lucchetti; Clara Di Mario; Barbara Tolusso; Giusy Peluso; Elisa Gremese
Journal:  Clin Rheumatol       Date:  2020-10-03       Impact factor: 2.980

5.  Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood-Brain Barrier of Human Brain and Glioblastoma.

Authors:  Xun Bao; Jianmei Wu; Youming Xie; Seongho Kim; Sharon Michelhaugh; Jun Jiang; Sandeep Mittal; Nader Sanai; Jing Li
Journal:  Clin Pharmacol Ther       Date:  2019-12-10       Impact factor: 6.875

Review 6.  Importance of Drug Pharmacokinetics at the Site of Action.

Authors:  M L Rizk; L Zou; R M Savic; K E Dooley
Journal:  Clin Transl Sci       Date:  2017-02-03       Impact factor: 4.689

Review 7.  Towards Improvements for Penetrating the Blood-Brain Barrier-Recent Progress from a Material and Pharmaceutical Perspective.

Authors:  Quanguo He; Jun Liu; Jing Liang; Xiaopeng Liu; Wen Li; Zhi Liu; Ziyu Ding; Du Tuo
Journal:  Cells       Date:  2018-03-23       Impact factor: 6.600

Review 8.  Recent Progress in Microfluidic Models of the Blood-Brain Barrier.

Authors:  Lili Jiang; Shu Li; Junsong Zheng; Yan Li; Hui Huang
Journal:  Micromachines (Basel)       Date:  2019-06-05       Impact factor: 2.891

9.  Neural production of kynurenic acid in Caenorhabditis elegans requires the AAT-1 transporter.

Authors:  Lin Lin; George A Lemieux; Osatohanmwen Jessica Enogieru; Kathleen M Giacomini; Kaveh Ashrafi
Journal:  Genes Dev       Date:  2020-07-16       Impact factor: 11.361

Review 10.  Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview.

Authors:  Courtney Perry; Grace Davis; Todd M Conner; Tao Zhang
Journal:  Curr Pharmacol Rep       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.